Trametinib dimethyl sulfoxide is the main compound in the Mekinist drug, used to treat melanoma, a type of skin cancer, produced by the GlaxoSmithKline laboratory.
This medicine is found in the form of a tablet, with a concentration of 0.5 mg, 1 mg and 2 mg. Mekinist is a prescription medication used to treat people with this type of skin cancer.
Indications
For the treatment of patients with metastatic melanoma, which cannot be operated on, or with BRAF V600E or V600K, mutations detected by an FDA approved test.
Side effects
Occurring in 10% of Mekinist treated patients, some symptoms such as: rash, dermatitis, dry skin, itching, paronychia, diarrhea, stomatitis, abdominal pain, lymphedema, hypertension, hemorrhage, can compromise fertility, among others. Mekinist can cause cardiomyopathy, severe visual disturbances that can lead to blindness, interstitial lung disease (or pneumonitis), hypertension. Patients are advised to notify their doctor immediately in case of any signs or symptoms.
How to use
The recommended dose is 2 mg orally, once a day until disease progression or unacceptable toxicity. Take at least 1 hour before or 2 hours after a meal. Do not take a dose within 12 hours of the next dose.
Contraindication
Lactating women, people with reproductive potential. Mekinist should not be used to treat people who have received a BRAF inhibitor for the treatment of melanoma.
